Our Take
Real improvement over the 60% baseline, but one-year data from 54 patients is early; the durable outcome that matters (five-year survival, quality-of-life metrics) remains unproven.
Why it matters
Muscle-invasive bladder cancer normally requires surgical removal of the bladder, a life-altering procedure requiring permanent urinary diversion. A non-surgical path that holds for longer periods would shift treatment for roughly 25% of all bladder cancer patients.
Do this week
Oncologists: flag durvalumab plus chemoradiation as a clinical trial option for newly diagnosed muscle-invasive bladder cancer patients before recommending cystectomy.
Phase 2 trial shows 85% one-year survival without surgery
The RAD-IO trial tested adding durvalumab (an immunotherapy) to chemotherapy and radiotherapy in 54 patients with muscle-invasive bladder cancer, a form where tumours have grown into the muscle wall. After 12 months, 46 of the 54 patients (85% per company-reported data) had no cancer recurrence. This compares to a 60% one-year recurrence-free rate in prior chemoradiation-only trials, also without surgery.
The trial was led by Professor Nick James at The Institute of Cancer Research, London and Royal Marsden NHS Foundation Trust and was presented at the American Society of Clinical Oncology annual meeting. All patients avoided surgical removal of the bladder (cystectomy), which normally requires a permanent urinary diversion system.
Muscle-invasive bladder cancer affects one in four bladder cancer patients
Cystectomy is considered the standard of care for muscle-invasive disease because the cancer has already penetrated deep tissue. The operation is major surgery with lasting consequences: patients require an external collection bag, catheterised pouch, or reconstructed bladder using bowel tissue. Quality of life, sexual function, and continence all change permanently.
A 25-percentage-point improvement in one-year recurrence rates (60% to 85%) is clinically meaningful. If the effect holds beyond 12 months and extends to overall survival, this could shift the initial treatment paradigm from "surgery first" to "chemoradiation plus immunotherapy, surgery if relapse."
The caveat is timing and scale. This is phase 2 data from a single trial in 54 patients. Long-term outcomes (three-, five-year survival) are unknown. Phase 3 trials, which typically enrol hundreds of patients across multiple sites, will determine whether the benefit is durable and reproducible.
When to discuss this with newly diagnosed patients
For oncologists treating muscle-invasive bladder cancer, durvalumab plus chemoradiation is not yet standard of care outside a trial. It is appropriate to discuss as an investigational option for eligible patients before recommending upfront cystectomy, particularly those concerned about surgical morbidity or quality of life. Ensure informed consent covers the lack of long-term data.
For patients: ask whether you are a candidate for a clinical trial testing durvalumab-based non-surgical approaches. If cystectomy is recommended, request discussion of ongoing trials in your institution or nearby centres.